Dr. Bekaii-Saab explains the best sequencing approach for second-line therapy when using FOLFIRINOX in the first line.

In this video, Dr. Bekaii-Saab discusses which patient is a candidate for a modified regimen of gemcitabine/nab-paclitaxel, as well as the differences in side effects and overall survival.

Dr. Picozzi discusses the role of maintenance therapy in pancreatic cancer and if there are any studies currently going on in that area.

Dr. Khorana discusses the role of neoadjuvant chemotherapy in pancreatic cancer.

Dr. Ramanathan discusses ongoing clinical trials in both front-line and second-line therapy for advanced metastatic pancreatic cancer, including immuno-oncology studies.

Dr. Khorana discusses the role of a multidisciplinary team in deciding which pancreatic cancer patients should be offered the option of tumor resection, and the process by which that decision is made.

Dr. Bekaii-Saab discusses new options for first-, second- and third-line therapy in advanced metastatic pancreatic cancer, as well as factors that must be considered in selecting among these agents.

Join Dr. Ramanathan as he discusses oxaliplatin for the treatment of advanced metastatic pancreatic cancer in second-line therapy.

Dr. Bekaii-Saab discusses the key points that community providers should consider when determining the best treatment approach for patients with advanced metastatic pancreatic cancer.

Join Dr. Ramanathan as he discusses the role immunotherapy will have in advanced pancreatic cancer, including the potential for combination therapy and which agents are already approved.